维升药业-B(02561)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02561 维升药业-B

已收盘 09-02 16:08:07

19.490

-0.110

-0.56%

最高19.800	最低19.250	成交量5,200
今开19.500	昨收19.600	日振幅2.81%
总市值22.22亿	流通市值22.22亿	总股本1.14亿
成交额10.09万	换手率0.00%	流通股本1.14亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02561","market":"HK","secType":"STK","nameCN":"维升药业-B","latestPrice":19.49,"timestamp":1788336487006,"preClose":19.6,"halted":0,"volume":5200,"delay":0,"changeRate":-0.005612244897959335,"floatShares":113999999,"shares":113999999,"eps":-2.44,"marketStatus":"已收盘","change":-0.11,"latestTime":"09-02 16:08:07","open":19.5,"high":19.8,"low":19.25,"amount":100886,"amplitude":0.028061,"askPrice":19.8,"askSize":300,"bidPrice":19.28,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-2.424,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788399000000},"marketStatusCode":5,"adr":0,"listingDate":1742486400000,"exchange":"SEHK","adjPreClose":19.6,"openAndCloseTimeList":[[1788312600000,1788321600000],[1788325200000,1788336000000]],"volumeRatio":0.314389,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02561","defaultTab":"news","newsList":[{"id":"1176659075","title":"维升药业-B更新8月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1176659075","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176659075?lang=zh_cn&edition=full","pubTime":"2026-09-01 16:35","pubTimestamp":1788251737,"startTime":"0","endTime":"0","summary":"维升药业-B于2026年9月1日发布了截至2026年8月31日止的证券变动月报表，报告期内公司法定注册股本维持在5亿股，面值每股0.0001美元，注册股本总额为5万美元。公告显示，维升药业-B在本月内未发生任何新增发行、购回、注销或库藏股变动，股本结构保持稳定。月报由公司执行董事卢安邦签署，维升药业-B表示将继续严格遵守香港联交所《上市规则》及相关监管规定。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101027015","title":"维升药业-B（02561）公布董事会及三大委员会最新架构","url":"https://stock-news.laohu8.com/highlight/detail?id=1101027015","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101027015?lang=zh_cn&edition=full","pubTime":"2026-08-27 22:23","pubTimestamp":1787840615,"startTime":"0","endTime":"0","summary":"2026年8月27日，维升药业-B发布公告，列示董事会成员及其在三大专业委员会中的职能分工。公告显示，公司董事会由九名成员组成，其中执行董事1名、非执行董事5名、独立非执行董事3名。公告未披露其他财务或经营数据。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662085038","title":"维升药业-B(02561.HK)核心产品获批开启商业化 上半年实现收入3454.2万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662085038","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662085038?lang=zh_cn&edition=full","pubTime":"2026-08-27 22:22","pubTimestamp":1787840575,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02561","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153519418","title":"维升药业-B 2026年上半年营收3,454.20万元，经调整净亏损1.04亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1153519418","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153519418?lang=zh_cn&edition=full","pubTime":"2026-08-27 22:16","pubTimestamp":1787840190,"startTime":"0","endTime":"0","summary":"2026年上半年，维升药业-B实现营收3,454.20万元。经调整净亏损1.04亿元，同比上一年同期的1.18亿元收窄约11.8%。经营活动所用现金流量净额为1.19亿元。从成本结构看，2026年上半年公司的销售及营销费用为3,577.20万元，约占营收的104%；管理费用为3,359.90万元，约占营收的97%；研发投入为3,737.40万元，占营收的108%。由于隆培生长激素在本期实现了首批商业化销售，带动整体收入增长。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"维升药业-B 2026年上半年营收3,454.20万元，经调整净亏损1.04亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662085145","title":"维升药业-B(02561.HK)：YAO Zhengbin  (Bing)辞任独立非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2662085145","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662085145?lang=zh_cn&edition=full","pubTime":"2026-08-27 22:16","pubTimestamp":1787840175,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02561","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660865794","title":"维升药业-B(02561.HK)拟8月27日举行董事会会议以审批中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2660865794","media":"中金财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660865794?lang=zh_cn&edition=full","pubTime":"2026-08-17 17:17","pubTimestamp":1786958226,"startTime":"0","endTime":"0","summary":"格隆汇8月17日丨维升药业-B(02561.HK)公告，谨定于2026年8月27日(星期四)举行董事会会议，以考虑及通过集团截至2026年6月30日止6个月中期业绩，以及处理其他事项。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260817/32337218.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02561","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195388155","title":"维昇药业-B拟于8月27日召开董事会审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1195388155","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195388155?lang=zh_cn&edition=full","pubTime":"2026-08-17 16:36","pubTimestamp":1786955768,"startTime":"0","endTime":"0","summary":"维昇药业-B8月17日公告称，公司董事会已排期于2026年8月27日（星期四）召开会议，审议并通过本集团截至2026年6月30日止六个月的中期业绩，并处理其他相关事项。公司强调，香港交易及结算所有限公司及香港联合交易所有限公司对本公告内容概不负责，对其准确性或完整性亦不发表任何声明，并且明确表示不承担任何因依赖该公告而产生的损失责任。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190158216","title":"维昇药业-B更新7月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1190158216","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190158216?lang=zh_cn&edition=full","pubTime":"2026-08-03 16:59","pubTimestamp":1785747590,"startTime":"0","endTime":"0","summary":"维昇药业-B于2026年8月3日发布截至2026年7月31日的股份变动月报表。已发行普通股数量为113,753,364股，库藏股数量为173,500股，合计113,926,864股，与上月底持平。维昇药业-B表示，本次股份变动事项均已符合香港联交所《上市规则》及其他适用法律法规的规定。截至2026年7月31日，公司总股本结构保持稳定。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654902660","title":"港股异动 | 维升药业-B(02561)涨超5% 维臻高®商业化销售逐步放量 公司将实现向“产品兑现”稳步过渡","url":"https://stock-news.laohu8.com/highlight/detail?id=2654902660","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654902660?lang=zh_cn&edition=full","pubTime":"2026-07-27 15:40","pubTimestamp":1785138023,"startTime":"0","endTime":"0","summary":"消息面上，此前维升药业核心产品长效生长激素隆培生长激素正式获批上市，适用于3岁及以上儿童、青少年生长激素缺乏症的治疗，也意味着维升药业开始进入商业化兑现周期。随着维臻高的商业化销售逐步放量并贡献业绩收入，公司将实现向“产品兑现”的稳步过渡，其估值中枢亦将随之获得更为坚实的基本面支撑。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1472528.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK4588","BK1161","02561","VXUS","KCAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652215574","title":"维升药业-B(02561)授出合共 51.41万份股份奖励","url":"https://stock-news.laohu8.com/highlight/detail?id=2652215574","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652215574?lang=zh_cn&edition=full","pubTime":"2026-07-20 20:33","pubTimestamp":1784550839,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维升药业-B(02561)发布公告，于2026年7月20日，本公司根据本计划向19名为本公司高级管理层及本集团雇员的合资格承授人(承授人)授出合共 51.41万份股份奖励，惟须待承授人接纳方可作实。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469987.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02561","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128799711","title":"维昇药业-B（02561）向19名员工授出51.41万股奖励股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1128799711","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1128799711?lang=zh_cn&edition=full","pubTime":"2026-07-20 20:31","pubTimestamp":1784550717,"startTime":"0","endTime":"0","summary":"2026年7月20日，维昇药业-B公告称，董事会根据公司首次公开发售后股份奖励计划，于同日向19名公司高级管理层及集团员工授出合计514,068份股份奖励，认购价为零。授出当日公司股份收市价为每股18.90港元。根据奖励计划规定，股份奖励自公司股份于2025年3月21日上市之日起10年内有效，所有在2035年3月21日前仍未归属的奖励股份将被无代价没收。根据公告，本次授予已获董事会批准，且不涉及向任何承授人提供财务资助。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649195162","title":"港股异动 | 维升药业-B(02561)盘中涨超7% 北京大学第三医院正式引进全球首款PTH疗法“帕罗培特立帕肽”","url":"https://stock-news.laohu8.com/highlight/detail?id=2649195162","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649195162?lang=zh_cn&edition=full","pubTime":"2026-07-08 10:03","pubTimestamp":1783476228,"startTime":"0","endTime":"0","summary":"维升药业-B(02561)盘中涨超7%，截至发稿，涨4.7%，报20.96港元。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20260708/20260708100848_58643.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260708/20260708100848_58643.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1464517.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["VXUS","02561","KCAI","BK4585","BK1161","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151732439","title":"维昇药业-B更新6月股份变动月报，总股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1151732439","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1151732439?lang=zh_cn&edition=full","pubTime":"2026-07-06 16:53","pubTimestamp":1783327999,"startTime":"0","endTime":"0","summary":"维昇药业-B于2026年7月6日披露截至2026年6月30日的股份变动月报。公告显示，公司法定股本为500,000,000股普通股，面值为每股0.0001美元，合计50,000美元，与上月一致。本月末已发行股份共计113,753,364股，较上月减少123,800股；库存股份数由49,700股增至173,500股，总股本维持在113,926,864股不变。报告期内未有新增发售或注销情况，相关股份变动主要由于公司在6月回购合计123,800股并将其持作库存股份。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648090055","title":"维升药业-B（02561）盘中涨近30%背后：市场聚焦核心产品放量，维臻高®商业化再提速","url":"https://stock-news.laohu8.com/highlight/detail?id=2648090055","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648090055?lang=zh_cn&edition=full","pubTime":"2026-07-02 18:32","pubTimestamp":1782988323,"startTime":"0","endTime":"0","summary":"7月2日，港股医药板块全线爆发，其中维升药业-B盘中放量飙升近30%，领跑整个创新药板块。截至当日收市，维升药业全日涨幅达25.13%，收至25港元，表现十分亮眼。今年1月，公司核心产品长效生长激素隆培生长激素正式获批上市，适用于3岁及以上儿童、青少年生长激素缺乏症的治疗，也意味着维升药业开始进入商业化兑现周期。2026年维升药业正以进口方式进行商业化，计划2028年实现技术转移及本地化生产。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462440.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02561"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648573106","title":"港股异动 | 维升药业-B(02561)早盘涨超15% 公司近期与镁信健康达成项目合作 探索多元支付新模式","url":"https://stock-news.laohu8.com/highlight/detail?id=2648573106","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648573106?lang=zh_cn&edition=full","pubTime":"2026-07-02 10:31","pubTimestamp":1782959502,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维升药业-B早盘涨超15%，截至发稿，涨15.22%，报23.02港元，成交额148.2万港元。消息面上，维升药业近日宣布，与中国领军医药多元支付平台镁信健康达成项目合作。双方将充分发挥各自在创新疗法与健康服务领域的资源优势，共同探索提升内分泌疾病创新疗法可及性与可支付性的多元路径，助力中国患者更便捷地获益于全球前沿的治疗方案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462152.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK4588","02561","VXUS","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648573101","title":"港股异动 | 维升药业-B(02561.HK)早盘涨超15% 公司近期与镁信健康达成项目合作 探索多元支付新模式","url":"https://stock-news.laohu8.com/highlight/detail?id=2648573101","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648573101?lang=zh_cn&edition=full","pubTime":"2026-07-02 10:31","pubTimestamp":1782959502,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02561"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647379633","title":"维升药业-B(02561)6月29日斥资8.46万港元回购4300股","url":"https://stock-news.laohu8.com/highlight/detail?id=2647379633","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647379633?lang=zh_cn&edition=full","pubTime":"2026-06-29 19:59","pubTimestamp":1782734357,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维升药业-B(02561)发布公告，于2026年6月29日，该公司斥资8.46万港元回购4300股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1460567.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02561"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122246339","title":"维昇药业-B 6月29日回购约0.43万股，耗资约8.46万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1122246339","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122246339?lang=zh_cn&edition=full","pubTime":"2026-06-29 19:57","pubTimestamp":1782734226,"startTime":"0","endTime":"0","summary":"维昇药业-B于2026年6月29日公布翌日披露报表，披露6月29日于香港联合交易所场内回购股份的具体信息。本次回购股份数量为4,300股，占回购前已发行股本约0.004%。回购价格每股介乎港币19.18元至港币20元，涉及总金额84,641港元，折合约8.46万港元。回购完成后，公司已发行股本为113,753,364股，库藏股数量增加至173,500股，总发行股本维持在113,926,864股。根据公告，公司确认已遵守香港联交所证券上市规则及相关法律法规。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"维昇药业-B 6月29日回购约0.43万股，耗资约8.46万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646357787","title":"维升药业-B(02561)委任Roy Paul Khoury、Sherrie Lynn Glass及Michael J. Chang为非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2646357787","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646357787?lang=zh_cn&edition=full","pubTime":"2026-06-26 20:48","pubTimestamp":1782478120,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维升药业-B(02561)发布公告，经股东于股东周年大会上批准后，委任Roy Paul Khoury先生、Sherrie Lynn Glass女士及Michael J. Chang先生为非执行董事已自2026年6月26日起生效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1459735.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02561","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167346466","title":"维昇药业-B6月23日回购0.40万股股份，涉资约7.68万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1167346466","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167346466?lang=zh_cn&edition=full","pubTime":"2026-06-23 20:15","pubTimestamp":1782216957,"startTime":"0","endTime":"0","summary":"维昇药业-B于2026年6月23日发布翌日披露报表，宣布于当日于香港联交所场内回购0.40万股普通股，占紧接回购前已发行股本约0.004%。该批股份每股回购价格介乎每股19.17港元至19.24港元，总金额约7.68万港元。回购授权于2025年6月27日获股东大会通过，公司依照授权可回购股份总数为11,392,686股，截至目前已在香港联交所或其他证券交易所合计回购169,200股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"维昇药业-B6月23日回购0.40万股股份，涉资约7.68万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.visenpharma.com","stockEarnings":[{"period":"1week","weight":-0.019},{"period":"1month","weight":0.0177},{"period":"3month","weight":-0.0522},{"period":"6month","weight":-0.3936},{"period":"1year","weight":-0.5662},{"period":"ytd","weight":-0.4024}],"compareEarnings":[{"period":"1week","weight":-0.0071},{"period":"1month","weight":-0.0214},{"period":"3month","weight":-0.0118},{"period":"6month","weight":0.0003},{"period":"1year","weight":-0.0112},{"period":"ytd","weight":-0.0117}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"维昇药业是一家主要从事开发并商业化颠覆式内分泌疗法的投资控股公司。该公司的主要在研产品包括隆培促生长素、那韦培肽和帕罗培特立帕肽。隆培促生長素用于治疗3至17岁儿童生长激素缺乏症患者。那韦培肽是一款用于治疗2至10岁软骨发育不全儿童患者的疾病修复疗法。帕罗培特立帕肽是一款用于治疗成人甲状旁腺功能减退症的治疗方法。该公司处于研发后期、产品接近商业化。","exchange":"SEHK","name":"维升药业-B","nameEN":"VISEN PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"维升药业-B(02561)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供维升药业-B(02561)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"维升药业-B,02561,维升药业-B股票,维升药业-B股票老虎,维升药业-B股票老虎国际,维升药业-B行情,维升药业-B股票行情,维升药业-B股价,维升药业-B股市,维升药业-B股票价格,维升药业-B股票交易,维升药业-B股票购买,维升药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"维升药业-B(02561)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供维升药业-B(02561)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}